Get the Stockscreener App
1.585
4.28%
0.065
After Hours:
1.65
0.065
+4.10%
Aldeyra Therapeutics Inc stock is traded at $1.585, with a volume of 1.23M.
It is up +4.28% in the last 24 hours and down -13.39% over the past month.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
See More
Previous Close:
$1.52
Open:
$1.53
24h Volume:
1.23M
Relative Volume:
0.90
Market Cap:
$95.61M
Revenue:
-
Net Income/Loss:
$-27.37M
P/E Ratio:
-3.482
EPS:
-0.4552
Net Cash Flow:
$-25.99M
1W Performance:
-6.76%
1M Performance:
-13.39%
6M Performance:
-71.39%
1Y Performance:
-69.34%
1-Day Range:
$1.53
$1.61
1-Week Range:
$1.475
$1.78
52-Week Range:
$1.07
$6.175
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Name
Aldeyra Therapeutics Inc
Sector
Industry
Phone
781-761-4904
Address
131 HARTWELL AVENUE, LEXINGTON, MA
Compare ALDX vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
1.585 | 91.69M | 0 | -27.37M | -25.99M | -0.4552 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-03-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-02-24 | Resumed | H.C. Wainwright | Buy |
| Apr-27-22 | Resumed | H.C. Wainwright | Buy |
| Feb-08-21 | Initiated | H.C. Wainwright | Buy |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Oct-30-20 | Initiated | Jefferies | Buy |
| Oct-16-20 | Initiated | BTIG Research | Buy |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| May-12-20 | Initiated | Oppenheimer | Outperform |
| Dec-04-18 | Initiated | Citigroup | Buy |
| Sep-26-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Sep-13-18 | Initiated | Janney | Buy |
| Jan-26-18 | Initiated | Seaport Global Securities | Buy |
| Sep-26-16 | Initiated | H.C. Wainwright | Buy |
| Jul-01-16 | Initiated | Stifel | Buy |
| Jul-01-15 | Initiated | Canaccord Genuity | Buy |
| Mar-25-15 | Initiated | Chardan Capital Markets | Buy |
| Mar-20-15 | Reiterated | H.C. Wainwright | Buy |
| Nov-18-14 | Initiated | H.C. Wainwright | Buy |
| Jun-19-14 | Initiated | Aegis Capital | Buy |
View All
Aldeyra Therapeutics Inc Stock (ALDX) Latest News
Aldeyra Therapeutics Inc (ALDX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
BlackRock (ALDX holder) discloses 1.7% Aldeyra Therapeutics stake in amended 13G - Stock Titan
Aldeyra Therapeutics Inc (ALDX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aldeyra Therapeutics Inc (ALDX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Aldeyra Therapeutics, Inc. Revenue Breakdown – NASDAQ:ALDX - TradingView
ALDX|Aldeyra Therapeutics Inc|Price:1.520|Chg%:-0.030 - TradingKey
Aldeyra Therapeutics Inc (ALDX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Aldeyra Therapeutics Inc (ALDX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aldeyra Therapeutics Inc (ALDX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ALDX Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Aldeyra Therapeutics Inc (ALDX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Investors to Reach Out - ACCESS Newswire
Price to sales forward of Aldeyra Therapeutics, Inc. – FWB:137 - TradingView
Revenue per share of Aldeyra Therapeutics, Inc. – FWB:137 - TradingView
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Stockholders to Reach Out - ACCESS Newswire
2026-07-19 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Stockholders to Reach Out | NDAQ:ALDX | Press Release - Stockhouse
Aldeyra Therapeutics Inc. (ALDX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Aldeyra Therapeutics to seek Type D meeting with FDA on reproxalap NDA resubmission - TradingView
Aldeyra Therapeutics (NASDAQ: ALDX) advances FDA dialogue on reproxalap NDA - Stock Titan
Understanding the Setup: (ALDX) and Scalable Risk - Stock Traders Daily
ALDX FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026 - AOL.com
Aldeyra Therapeutics: What Comes Next After Reproxalap's Third CRL (NASDAQ:ALDX) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Shareholders to Connect - ACCESS Newswire
ALDX EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026 - AOL.com
ALDX Shareholder Alert: Aldeyra Therapeutics, Inc. Securities Class Action LawsuitInvestors Should Contact The Gross Law Firm - AOL.com
Aldeyra Therapeutics (ALDX) Posts Modest Gain Amid Biotech Sector RecoveryReversal Setup Alerts - DonanımHaber
Levicept Ltd (ALDX) Appoints Darlene Deptula-Hicks as CFO Amid P - GuruFocus
Levicept Appoints Darlene Deptula-Hicks as CFO - GlobeNewswire Inc.
Aldeyra Therapeutics Q1 2026 Earnings: Narrower Loss Beats Estimates, Pipeline Progress Remains Key - DonanımHaber
Why Did ALDX Stock Tank 70% Today? - Stocktwits
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Shareholders to Reach Out - ACCESS Newswire
ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Spotlight On Aldeyra Therapeutics And 2 Other Prominent Penny Stocks - Sahm
ALDX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Aldeyra Therapeutics, Inc. Actuals & Estimates (TRADEGATE:137) - TradingView
ALDX News | ALDEYRA THERAPEUTICS INC (NASDAQ:ALDX) - ChartMill
The Technical Signals Behind (ALDX) That Institutions Follow - Stock Traders Daily
ALDX Stockholders Have Opportunity to Lead Aldeyra Therapeutics - The National Law Review
ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds - The National Law Review
Aldeyra Therapeutics (ALDX) Edges Higher Near Support; Key Resistance AheadETF Outflow Streak - dars.gov.et
Aldeyra Therapeutics, Inc.(NasdaqCM:ALDX) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
Aldeyra Therapeutics, Inc.(NasdaqCM:ALDX) dropped from Russell 2500 Growth Benchmark - marketscreener.com
Aldeyra Therapeutics, Inc.(NasdaqCM: ALDX) dropped from Russell 2000 Value Benchmark - marketscreener.com
Aldeyra Therapeutics, Inc.(NasdaqCM:ALDX) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Aldeyra Therapeutics, Inc.(NasdaqCM:ALDX) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Aldeyra Therapeutics, Inc.(NasdaqCM: ALDX) dropped from Russell 2000 Dynamic Index - marketscreener.com
Aldeyra Therapeutics, Inc.(NasdaqCM: ALDX) dropped from Russell 3000E Index - marketscreener.com
Aldeyra Therapeutics Inc Stock (ALDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):